We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+12.57%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$750M
AUM Growth
+$262M
Cap. Flow
+$205M
Cap. Flow %
27.3%
Top 10 Hldgs %
28.71%
Holding
137
New
15
Increased
36
Reduced
40
Closed
5

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$14.3M
2
ALGN icon
Align Technology
ALGN
+$13.8M
3
WBA
Walgreens Boots Alliance
WBA
+$13.5M
4
AMGN icon
Amgen
AMGN
+$12M
5
CNC icon
Centene
CNC
+$9.49M

Top Sells

Rank Stock Value
1
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$4.67M
2
SYK icon
Stryker
SYK
+$4.15M
3
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$1.91M
4
BDX icon
Becton Dickinson
BDX
+$1.79M
5
ZBH icon
Zimmer Biomet
ZBH
+$1.75M

Sector Composition

Rank Sector Weight
1 Healthcare 92.09%
2 Financials 0.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACHN
126
DELISTED
Achillion Pharmaceuticals
ACHN
$417K 0.06%
99,000
-141,000
-59% -$585K
NVAX icon
127
Novavax
NVAX
$1.35B
$416K 0.06%
16,250
– –
WBMD
128
DELISTED
WebMD Health Corp.
WBMD
$390K 0.05%
7,400
– –
AAC
129
DELISTED
AAC Holdings
AAC
$384K 0.05%
45,000
– –
MYGN icon
130
Myriad Genetics
MYGN
$584M
$250K 0.03%
13,000
-1,000
-7% -$17.7K
SGRY icon
131
Surgery Partners
SGRY
$2.09B
$205K 0.03%
10,500
-4,500
-30% -$87.4K
CERS icon
132
Cerus
CERS
$627M
$134K 0.02%
+30,000
New +$127K
BIB icon
133
ProShares Ultra NASDAQ Biotechnology
BIB
$84.1M
– –
-20,500
Closed -$818K
LABU icon
134
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$617M
– –
-1,259
Closed -$788K
EIGR
135
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-111
Closed -$39K
INSY
136
DELISTED
Insys Therapeutics, Inc.
INSY
– –
-115,000
Closed -$1.06M
ARIA
137
DELISTED
Ariad Pharmaceuticals Inc
ARIA
– –
-375,000
Closed -$4.67M
2 3 4 5
6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2017 Portfolio in Review

As of Q1 2017, Bellevue Group held 137 positions worth $750M, up 54% from $488M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Group deployed $205M of net new capital in Q1 2017, opening 15 new positions and adding to 36 existing holdings. Its largest new stake was Align Technology: 136,200 shares worth $15.6M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Stryker, an estimated $4.15M trimmed.

  • Bellevue Group's largest Q1 2017 buy was Align Technology: 136,200 shares worth $15.6M.
  • Bellevue Group added most to Elevance Health in Q1 2017, an estimated $14.3M increase.
  • Bellevue Group's biggest Q1 2017 reduction was Stryker, cutting an estimated $4.15M.
  • Bellevue Group fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $4.67M.
  • Bellevue Group's ten largest holdings make up 29% of its $750M portfolio in Q1 2017.
  • Bellevue Group opened 15 new positions and closed 5 in Q1 2017.
  • Bellevue Group's portfolio value rose 54% quarter-over-quarter to $750M.

Based on Bellevue Group's 13F filing for Q1 2017, filed 11 May 2017.